Non-steroidal Anti-inflammatory Drugs Market (2026 - 2033)

Non-steroidal Anti-inflammatory Drugs Market Summary

The global non-steroidal anti-inflammatory drugs market size was valued at USD 23.8 billion in 2025 and is projected to grow from USD 25.0 billion in 2026 to USD 37.6 billion by 2033, at a CAGR of 6.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 42.7% in 2025. The growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market is driven by the global rise in chronic pain prevalence and the increasing geriatric population.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Key Market Trends & Insights

• By disease indication: Arthritis segment led the market with the largest revenue share of 37.6% in 2025.
• By route of administration: Oral segment led the market with the largest revenue share of 52.1% in 2025.
• By distribution channel: Retail pharmacy segment led the market with the largest revenue share of 45.7% in 2025.

Regional Highlights

• Largest regional market: North America (42.7% revenue share, 2025)
• Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
• By country: The U.S. held the largest market share in 2025.

Market Size & Forecast

• Market size in 2025: USD 23.8 Billion
• Estimated market size in 2026: USD 25.0 Billion
• Projected market size by 2033: USD 37.6 Billion
• CAGR (2026-2033): 6.0%

Expanded demand for OTC NSAIDs and broader applications in conditions such as headaches, migraines, toothaches, and menstrual pain further support growth projections. Additionally, a diverse NSAIDs product portfolio and new product approvals and launches contribute to market momentum during the forecast period. The increasing prevalence of arthritis and other pain-related disorders is expected to support industry growth over the forecast period. In 2024, nearly one-quarter of U.S. adults are estimated to have arthritis, equating to over 350 million cases globally. The most prevalent types include osteoarthritis, affecting over 32.5 million Americans, and rheumatoid arthritis, impacting approximately 1.36 million. Among those diagnosed, nearly 50% are aged 65 and older, while the condition significantly affects women. Racial disparities are evident, with 41.3 million non-Hispanic white adults, 6.1 million non-Hispanic Black adults, and 4.4 million Hispanic adults reported as affected.

To learn more about this report, Download Free Sample Report

The geriatric population is more susceptible to diseases such as CVDs, cancer, diabetes, chronic pain, arthritis, and others. Thus, the rising geriatric population across the globe is expected to support market growth. WHO’s October 2024 report highlights the rapid aging of global populations, noting that by 2050, 80% of older adults will reside in low- and middle-income countries. This shift emphasizes the need for robust health systems to address age-associated conditions like osteoarthritis and chronic pain, commonly managed with NSAIDs. As demand grows for NSAID-based treatments in these regions, industry expansion is expected, especially where aging demographics drive accessibility improvements and policy support. These factors align with anticipated non-steroidal anti-inflammatory drugs market growth, given rising needs in chronic pain management.

The growth of the NSAIDs market is driven by a diverse product portfolio. Notably, Pfizer Inc. produces Ketorolac tromethamine, indicated for treating moderate to severe acute pain requiring opioid-level analgesia. Additionally, GSK's Excedrin, a combination of paracetamol, aspirin, and caffeine, remains a top choice for headache relief. The strong industry presence of established brands and the rising availability of combination therapies are expected to enhance growth prospects during the forecast period further.

Market Dynamics

The non-steroidal anti-inflammatory drugs (NSAIDs) market is experiencing steady growth due to the increasing prevalence of musculoskeletal disorders, arthritis, postoperative pain, sports injuries, and other acute and chronic pain conditions. The market continues to benefit from the widespread use of NSAIDs as first-line therapies for pain, inflammation, and fever management across both prescription and over-the-counter segments. Broad product availability, the presence of well-established branded and generic formulations, and easy access through retail and online pharmacies support consistent product demand. In addition, the growing aging population, rising number of orthopedic procedures, and increasing incidence of chronic inflammatory conditions are contributing to greater use of NSAID therapies. Pharmaceutical companies are also focusing on developing formulations with improved gastrointestinal safety, longer duration of action, and convenient dosage forms such as topical gels, patches, and sustained-release oral formulations. These factors, along with continued product innovation and broad clinical acceptance, are supporting the sustained growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market.

Analyst Perspective

The non-steroidal anti-inflammatory drugs (NSAIDs) market remains well established due to the continued use of these therapies for managing pain, inflammation, and fever across multiple disease indications. The market is characterized by a combination of branded and generic products, with competition focused on product availability, pricing, formulation development, and distribution reach. Pharmaceutical companies are expanding topical formulations and sustained-release products to address patient demand for localized treatment and improved convenience. Bayer AG, Pfizer Inc., GSK plc, and Johnson & Johnson Services, Inc. continue to maintain strong market positions through established product portfolios and broad distribution networks, while Dr. Reddy's Laboratories Ltd., Viatris Inc., and Teva Pharmaceutical Industries Ltd. strengthen competition by expanding their generic NSAID offerings and global market presence.

Disease Indication Insights

Based on disease indication, the arthritis segment led the market with the largest revenue share of 37.6% in 2025, due to the increasing prevalence of arthritis and a growing aging population. The rise in treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics, has further fueled industry growth. Additionally, heightened awareness of arthritis and advancements in treatment technologies have contributed to this segment's dominance. Market players are also focusing on innovative product development to address the diverse needs of arthritis patients.

The migraine segment is projected to experience significant growth opportunities during the forecast period. This is driven by the increasing prevalence of migraines and advancements in treatment options, including prescription medications and over-the-counter (OTC) products. The demand for innovative therapies, such as neuromodulation devices and biologics, is also expected to rise. Additionally, greater awareness of migraine management and a growing focus on personalized treatment approaches contribute to industry expansion. Key players are investing in research and development to address unmet needs, positioning the migraine segment for robust growth.

Route of Administration Insights

Based on route of administration, the oral segment led the market with the largest revenue share of 52.1% in 2025, due to its convenience and effectiveness in delivering medications. Oral administration is preferred by both patients and healthcare providers for its ease of use, adherence, and versatility across various therapeutic areas, including pain management and chronic conditions. The rise in demand for over-the-counter (OTC) pain relief and prescription medications further fuels this segment's growth. Additionally, advancements in formulation technology enhance the bioavailability of oral drugs, making them more appealing to consumers. This trend is expected to continue as the industry evolves.

To learn more about this report, Download Free Sample Report

The topical segment is anticipated to experience the fastest CAGR during the forecast period, driven by increasing consumer preference for non-invasive and localized treatment options. The rising prevalence of skin-related ailments, such as psoriasis and eczema, along with the growing demand for pain management solutions, are contributing to this segment's expansion. Innovations in formulation technology, including enhanced penetration and sustained release, further bolster industry interest. Moreover, the growing trend of self-medication is expected to increase the adoption of topical treatments, enhancing their industry presence.

Distribution Channel Insights

Based on distribution Channel, the retail pharmacy segment led the market with the largest revenue share of 45.7% in 2025, driven by its extensive distribution network and accessibility to consumers. Factors contributing to this dominance include the increasing demand for over-the-counter medications and the rising trend of self-medication among patients. Retail pharmacies offer a wide range of pharmaceutical products, ensuring convenience and prompt service, which enhances customer satisfaction. Furthermore, the growing prevalence of chronic diseases is propelling the demand for continuous medication, further solidifying the retail pharmacy’s industry position. Sources indicate that this segment’s growth is expected to continue, reflecting shifts in consumer behavior and healthcare delivery models.

The hospital pharmacy segment held the second largest market share, driven by high adoption rates of advanced pharmaceutical practices and increasing patient admissions. Hospital pharmacies play a crucial role in medication management, particularly for patients with complex conditions requiring specialized care. The rising emphasis on patient safety and personalized medicine further enhances the demand for hospital pharmacy services. Additionally, innovations in drug formulation and delivery systems contribute to the growth of this segment. The integration of technology in hospital pharmacies also supports efficient inventory management and improved patient outcomes.

Regional Insights

North America dominated the non-steroidal anti-inflammatory drugs market with the largest revenue share of 42.7% in 2025, the industry is expected to grow significantly, influenced by several key factors. A large number of manufacturers and strategic initiatives by leading companies are propelling market expansion.

To learn more about this report, Download Free Sample Report

Additionally, a rising incidence of chronic pain and arthritis is projected to further drive growth. According to CDC estimates, the prevalence of arthritis is set to increase substantially, with over 78.4 million adults anticipated to have a doctor-diagnosed arthritis condition by 2040. Prominent industry players, including Pfizer Inc., Johnson & Johnson Consumer Inc., and GSK Group of Companies, maintain a solid presence in North America, supporting continued market growth across the U.S., Canada, and Mexico.

U.S. Non-steroidal Anti-inflammatory Drugs Market Trends

The non-steroidal anti-inflammatory drugs market in the U.S. held the largest share in the North America region in 2025. driven by the increasing prevalence of chronic pain conditions and the growing demand for effective pain management solutions. The robust product offerings and innovative formulations from key players have bolstered industry growth. Additionally, the rising focus on over-the-counter (OTC) availability and the integration of NSAIDs into combination therapies are contributing factors. This segment is expected to maintain its dominance due to ongoing advancements in drug delivery systems and formulations.

Europe Non-steroidal Anti-inflammatory Drugs Market Trends

The Europe NSAIDs market is witnessing significant growth, driven by increasing awareness of pain management solutions and the rising prevalence of chronic pain conditions. Increased education on the effective use of NSAIDs for various ailments, coupled with the expansion of OTC availability, is propelling market expansion. Additionally, the growing aging population in Europe, which is more susceptible to conditions requiring pain relief, further stimulates demand for NSAIDs. Regulatory support for innovative formulations and the development of combination therapies also contribute to this industry growth.

The UK NSAIDs market is projected to grow significantly due to increasing awareness of pain management and the prevalence of chronic conditions. The National Health Service (NHS) emphasizes the importance of NSAIDs in treatment protocols, contributing to higher consumption rates. The presence of key pharmaceutical companies enhances industry competition and innovation. The UK government’s initiatives to promote effective pain management strategies further support market growth .

The non-steroidal anti-inflammatory drugs market in Germany represents a substantial share in Europe, driven by a strong healthcare system and high demand for effective pain relief medications. The adoption of combination therapies and the integration of NSAIDs in treatment plans for arthritis and other chronic conditions are notable trends. Regulatory support for over-the-counter NSAIDs contributes to industry accessibility, facilitating growth opportunities for manufacturers.

Asia Pacific Non-steroidal Anti-inflammatory Drugs Market Trends

The Asia Pacific NSAIDs industry is experiencing robust growth, attributed to rising healthcare expenditure and increased consumer awareness of pain management solutions. The region's aging population and a higher incidence of chronic diseases such as arthritis are significant factors driving demand. Key players are expanding their product offerings to cater to diverse consumer needs, enhancing market penetration.

China NSAIDs market is expanding rapidly due to a growing population and increased incidence of chronic pain conditions. The government's focus on improving healthcare infrastructure and access to medications supports this growth. The rising prevalence of lifestyle-related diseases has led to a surge in demand for effective pain management solutions, positioning NSAIDs as a crucial component of the pharmaceutical market.

The NSAIDs market in Japan is characterized by a high level of consumer awareness and an established healthcare system. The prevalence of geriatric populations and the increasing use of NSAIDs for managing chronic pain are driving factors. Innovative formulations and targeted therapies are gaining traction, supported by extensive research and development efforts from leading pharmaceutical companies.

Latin America Non-steroidal Anti-inflammatory Drugs Market Trends

The Latin America NSAIDs market is expected to significantly grow over the forecast period owing to increasing prevalence of chronic disorders requiring the use of NSAIDs and high demand for NSAIDs. Furthermore, the rising geriatric population susceptible to chronic illness leads to high demand for pain medications including NSAIDs.

Brazil NSAIDs market is witnessing steady growth, fueled by an increasing focus on healthcare accessibility and the prevalence of pain-related disorders. Government policies to expand healthcare coverage and improve drug availability support market expansion. The demand for affordable over-the-counter NSAIDs is rising, reflecting changing consumer preferences toward self-medication.

MEA Non-steroidal Anti-inflammatory Drugs Market Trends

The MEA NSAIDs market is growing due to rising awareness of chronic pain management and an increasing incidence of musculoskeletal disorders. The expanding pharmaceutical sectors in South Africa and the UAE enhance industry dynamics. Collaborative efforts between healthcare providers and pharmaceutical companies to improve access to NSAIDs also contribute to market growth.

Saudi Arabia's NSAIDs market is expanding as healthcare initiatives prioritize pain management. The country’s Vision 2033 framework aims to improve health outcomes, driving demand for effective pain relief solutions. The presence of both local and international pharmaceutical companies facilitates market competition, further enhancing product availability and consumer access to NSAIDs.

Key Non-steroidal Anti-inflammatory Drugs Company Insights

The competitive scenario in the NSAIDs industry is characterized by the presence of several key players, including Pfizer, Bayer, and Johnson & Johnson, each offering a range of products to meet diverse consumer needs. Market strategies focus on innovation, pricing, and distribution channels. Companies invest in research and development to create advanced formulations and combination therapies. The market also sees increased competition from generic brands, which offer cost-effective alternatives. Regulatory compliance and quality assurance remain critical for maintaining market position. Collaborations and partnerships enhance distribution capabilities and market reach.

Key Non-steroidal Anti-inflammatory Drugs Companies

The following key companies have been profiled for this study on the non-steroidal anti-inflammatory drugs (NSAIDs) market.

• Pfizer Inc.

• Bayer AG

• GSK plc

• Dr. Reddy’s Laboratories Ltd

• Viatris Inc

• Teva Pharmaceutical Industries Ltd.

• Johnson and Johnson Services, Inc.

• Merck & Co., Inc.

Recent Developments

• In April 2024, Glenmark Pharmaceuticals announced the U.S. FDA's approval of its Acetaminophen and Ibuprofen Tablets (250 mg/125 mg), classified as an OTC product. This formulation is bioequivalent to Haleon's Advil Dual Action with Acetaminophen, which generated approximately USD 84.1 million in sales over the past year. Glenmark aims to enhance its portfolio, with 195 products authorized in the U.S. and 52 ANDAs pending. The company focuses on therapeutic areas such as respiratory, dermatology, and oncology, operating globally with 11 manufacturing facilities.

• In February 2024, Hikma Pharmaceuticals launched COMBOGESIC IV in the U.S., providing a new opioid-free option for adult pain management. COMBOGESIC IV combines acetaminophen (1,000 mg) and ibuprofen (300 mg) for intravenous use, approved by the FDA in October 2023 for mild to moderate pain relief and as an adjunct for severe pain alongside opioids. The product’s dual-action approach aligns with the American Society of Anesthesiology’s multimodal pain management strategy, aiming for quicker and sustained relief. Originally developed by AFT Pharmaceuticals, COMBOGESIC IV is also marketed as MAXIGESIC IV outside the US.

• In December 2023, Scilex Holding Company filed a New Drug Submission to Health Canada for ELYXYB (celecoxib oral solution), aimed at treating acute migraines. ELYXYB is the only FDA-approved ready-to-use oral solution for migraines, showing efficacy in pain relief within 15 minutes. The Canadian migraine therapeutics market is projected to reach USD 400 million by 2025. Approval is anticipated in about 12 months. Scilex aims to provide alternatives for patients who do not respond to triptan therapies.

Global Non-steroidal Anti-inflammatory Drugs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global non-steroidal anti-inflammatory drugs market report on the basis of disease indication, route of administration, distribution channel, and region:

To learn more about this report, Download Free Sample Report

• Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)

  • Arthritis

  • Migraine

  • Ophthalmic Diseases

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

  • Oral

  • Topical

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The non-steroidal anti-inflammatory drugs market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each non-steroidal anti-inflammatory drugs segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The study adopted a commodity flow market analysis approach to estimate the size of the global non-steroidal anti-inflammatory drugs (NSAIDs) market. Key manufacturers and marketed NSAID products were identified across oral, topical, injectable, ophthalmic, and other formulations. Product benchmarking was conducted using company annual reports, investor presentations, regulatory filings, product labels, and published literature to evaluate product availability, pricing, regulatory status, and geographic presence. Revenue generated from key products was assessed using publicly available company information and validated through prescription volumes, over-the-counter sales, treatment patterns, healthcare utilization, and regional demand. Market estimates were further verified by analyzing product adoption across hospital pharmacies, retail pharmacies, and online pharmacies, along with the market share of leading manufacturers. Primary interviews with pharmaceutical manufacturers, distributors, healthcare professionals, and industry experts were conducted to validate assumptions, product positioning, utilization patterns, and regional market trends, ensuring accurate market estimates.

To learn more about this report, Download Free Sample Report

Delivered Customizations

This report has been delivered with the following In-depth customizations